Traws Pharma Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Werner Cautreels

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Werner Cautreels (72 yo)

less than a year

Mandato

Dr. Werner Cautreels, Ph.D. serves as Member of Advisory Board at Thuja Capital Management B.V. He also serves as Chief Executive Officer & Director of Traws Pharma, Inc. since April 01, 2024. He has been...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mark Guerin	Chief Financial Officer	8.2yrs	US$745.52k	0.052% € 6.7k
Victor Moyo	Chief Medical Officer of Oncology	1.3yrs	US$405.25k	0% € 0
Iain Dukes	Executive Chairman	less than a year	Nessun dato	0.48% € 62.9k
Werner Cautreels	CEO & Director	less than a year	Nessun dato	Nessun dato
Nikolay Savchuk	COO & Director	less than a year	Nessun dato	1.66% € 214.7k
Robert Redfield	Chief Medical Officer	less than a year	Nessun dato	Nessun dato
Charles Pauza	Chief Scientific Officer of Virology	less than a year	Nessun dato	Nessun dato

0.6yrs

Durata media

66yo

Età media

Gestione esperta: Il team dirigenziale di 0T20 non è considerato esperto (durata media 0.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Iain Dukes	Executive Chairman	less than a year	Nessun dato	0.48% € 62.9k
Werner Cautreels	CEO & Director	less than a year	Nessun dato	Nessun dato
Nikolay Savchuk	COO & Director	less than a year	Nessun dato	1.66% € 214.7k
Jack Stover	Independent Director	8.5yrs	US$126.72k	0.00030% € 38.9
Alan Williamson	Chairman of Scientific Advisory Board	7.9yrs	Nessun dato	Nessun dato
Stephen Nimer	Member of Scientific Advisory Board	19.7yrs	Nessun dato	Nessun dato
David Parkinson	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ross Donehower	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
George Vande Woude	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Anna Skalka	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Mary Shoemaker	Independent Director	4.6yrs	US$118.22k	0.0045% € 583.7
Luba Greenwood	Independent Director	less than a year	Nessun dato	Nessun dato

2.6yrs

Durata media

69yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 0T20 non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

Traws Pharma Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024

Traws Pharma, Inc. Announces Board Changes

High number of new directors

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

Recent updates

Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024

Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma, Inc. Announces Board Changes

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2023)

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

Full year 2023 earnings released: US$0.90 loss per share (vs US$0.91 loss in FY 2022)

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

New major risk - Share price stability

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Third quarter 2023 earnings released: US$0.23 loss per share (vs US$0.26 loss in 3Q 2022)

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.19 loss in 2Q 2022)

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.20 loss in 1Q 2022)

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$0.91 loss per share (vs US$0.96 loss in FY 2021)

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors

Onconova Therapeutics, Inc. Announces Board Appointments

Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.22 loss in 3Q 2021)

Onconova Therapeutics, Inc. Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Onconova Therapeutics, Inc. Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

Second quarter 2022 earnings released: EPS: US$0 (vs US$0.27 loss in 2Q 2021)

Onconova Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Onconova Therapeutics, Inc., Annual General Meeting, Aug 18, 2022

Onconova Therapeutics, Inc. Announces Executive Changes

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021)

Onconova Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma

Onconova Therapeutics, Inc. Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces the Publication of a Preclinical Study in the Journal Molecular Cancer

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

Onconova Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 11, 2021

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces Resignation of Richard C. Woodman, MD, Senior Vice President Chief Medical Officer

Onconova Therapeutics, Inc. Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

Manoj Maniar, Ph.D., Senior Vice President, Product Development departs from Onconova Therapeutics, Inc

Onconova Therapeutics Files Investigational New Drug Application for Multi-Kinase CDK4/6 Inhibitor ON 123300

Onconova Therapeutics, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Onconova Therapeutics, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione